BR112023005623A2 - Composições e métodos para modular simultaneamente expressão de genes - Google Patents

Composições e métodos para modular simultaneamente expressão de genes

Info

Publication number
BR112023005623A2
BR112023005623A2 BR112023005623A BR112023005623A BR112023005623A2 BR 112023005623 A2 BR112023005623 A2 BR 112023005623A2 BR 112023005623 A BR112023005623 A BR 112023005623A BR 112023005623 A BR112023005623 A BR 112023005623A BR 112023005623 A2 BR112023005623 A2 BR 112023005623A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
gene expression
simultaneously modulate
modulate gene
Prior art date
Application number
BR112023005623A
Other languages
English (en)
Inventor
Antony Selvaraj Justin
Pieter Zuideveld Klaas
Schaffhauser Herve
HILLMANN-WULLNER Petra
Metzger Friedrich
Original Assignee
Versameb Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Versameb Ag filed Critical Versameb Ag
Publication of BR112023005623A2 publication Critical patent/BR112023005623A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIÇÕES E MÉTODOS PARA MODULAR SIMULTANEAMENTE EXPRESSÃO DE GENES. A presente invenção se refere a composições de construtos de ácido polinucleico recombinantes compreendendo pelo menos uma sequência de ácidos nucleicos que codifica um siRNA capaz de se ligar a um RNAm alvo e pelo menos uma sequência de ácidos nucleicos que codifica um gene de interesse. Também é divulgado, na presente invenção, o uso das composições para tratar cânceres e para modular, simultaneamente, a expressão de dois ou mais genes.
BR112023005623A 2020-10-05 2021-10-04 Composições e métodos para modular simultaneamente expressão de genes BR112023005623A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063087643P 2020-10-05 2020-10-05
US202163213841P 2021-06-23 2021-06-23
PCT/IB2021/000682 WO2022074453A2 (en) 2020-10-05 2021-10-04 Compositions and methods for simultaneously modulating expression of genes

Publications (1)

Publication Number Publication Date
BR112023005623A2 true BR112023005623A2 (pt) 2023-04-25

Family

ID=78709494

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023005623A BR112023005623A2 (pt) 2020-10-05 2021-10-04 Composições e métodos para modular simultaneamente expressão de genes

Country Status (11)

Country Link
US (1) US20230322885A1 (pt)
EP (1) EP4225920A2 (pt)
JP (1) JP2023543915A (pt)
KR (1) KR20230082026A (pt)
AU (1) AU2021356243A1 (pt)
BR (1) BR112023005623A2 (pt)
CA (1) CA3192949A1 (pt)
IL (1) IL301510A (pt)
MX (1) MX2023003925A (pt)
TW (1) TW202228728A (pt)
WO (1) WO2022074453A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117693589A (zh) * 2021-06-23 2024-03-12 维萨梅布有限公司 用于调节基因表达的组合物和方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008148068A1 (en) * 2007-05-23 2008-12-04 Mannkind Corporation Multicistronic vectors and methods for their design
AU2013203610A1 (en) * 2012-06-20 2014-01-16 The Australian National University Improved Recombinant Viruses
WO2015148683A1 (en) * 2014-03-26 2015-10-01 Tocagen Inc. A retroviral vector having immune-stimulating activity
US20210155955A1 (en) * 2018-04-11 2021-05-27 Cancer Targeting Systems, Inc. Therapeutic constructs for treating cancer
US20210106667A1 (en) * 2018-05-03 2021-04-15 Duke University Vaccine compositions and methods for enhanced antigen-specific vaccination
BR112022012324A2 (pt) * 2019-12-23 2022-10-11 Versameb Ag Composições e métodos para modular simultaneamente expressão de genes

Also Published As

Publication number Publication date
AU2021356243A1 (en) 2023-06-08
WO2022074453A3 (en) 2022-06-09
MX2023003925A (es) 2023-05-08
US20230322885A1 (en) 2023-10-12
CA3192949A1 (en) 2022-04-14
IL301510A (en) 2023-05-01
WO2022074453A2 (en) 2022-04-14
JP2023543915A (ja) 2023-10-18
EP4225920A2 (en) 2023-08-16
TW202228728A (zh) 2022-08-01
KR20230082026A (ko) 2023-06-08

Similar Documents

Publication Publication Date Title
BR112022012324A2 (pt) Composições e métodos para modular simultaneamente expressão de genes
CO2017009954A2 (es) Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina
BR112021024786A2 (pt) Construção de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de rna, vacina, método para modificar uma célula ex vivo ou in vitro e célula modificada
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
BR112017009835A2 (pt) moléculas de ácido nucleico artificiais
BR112017010110A2 (pt) anticorpos contra cd73 e usos do mesmo
BR112017013599A2 (pt) composição farmacêutica, e, método para prevenir, tratar ou melhorar um ou mais sintomas de um tumor maligno associado à mutação de kras.
BR112016009465A2 (pt) Vírus herpes simplex oncolítico recombinante (ohsv), ácido nucleico o codificando, estoque viral e composição o compreendendo, bem como seu uso
BR112022004047A2 (pt) Proteínas de ligação multiespecíficas para o tratamento de câncer
BR112017018728A2 (pt) sistema de vetor para expressar a sequência de codificação de um gene de interesse em uma célula, célula hospedeira, composição farmacêutica, método para tratar e/ou prevenir uma patologia ou doença, uso de uma sequência de nucleotídeo de um sinal de degradação em um sistema de vetor e método para diminuir a expressão de uma proteína na forma truncada
CL2021001490A1 (es) Constructos de iarn modificados químicamente y usos de estos
BRPI0519690A2 (pt) composiÇÕes e mÉtodos para modular a expressço de genes usando oligonucleotÍdeos autoprotegidos
MX2022013945A (es) Nuevas proteinas de union a repeticiones de anquirina y sus usos.
BR112019002904A2 (pt) métodos e composições para transferência gênica direcionada
BR112022013236A2 (pt) Anticorpos anti-cd73 e usos dos mesmos
BR112021005777A2 (pt) Produtos e composições
BR112023005623A2 (pt) Composições e métodos para modular simultaneamente expressão de genes
ECSP22083174A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
DOP2022000229A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
BR112018010669A8 (pt) anticorpo anti-pcsk9 e utilização do mesmo
UY38503A (es) Constructos de arni para inhibir la expresión de pnpla3 y métodos de uso de estos
BR112022000628A2 (pt) Anticorpos anti-tigit e aplicação dos mesmos
BR112016011866A2 (pt) vetores de composições e métodos para induzir uma resposta imune potencializada usando vetores de poxvírus
BR112022006476A2 (pt) Oligonucleotídeos com análogos de nucleosídeos
BR112021021686A2 (pt) Moléculas inibidoras de ácido nucleico de fita dupla com fitas senso curtas